drugset / Trial / NCT00711464

Modafinil Effects on Cognition in Schizophrenia Patients

NCT00711464

Phase 4 Completed 29 enrolled University of California, Los Angeles
RandomizedSingle-groupQuadruple-blindTreatment

Summary

Patients with schizophrenia have problems in thinking, known as cognitive dysfunction. This includes many types of cognitive dysfunction, such as in attention, memory and language. These problems may explain why patients with schizophrenia think and act in unusual ways, and often have problems managing aspects of their lives that healthy adults take for granted. Unfortunately, the biochemical aspects of these dysfunctions are presently unknown, and it is not clear whether current psychiatric medications can improve these functions. A recent FDA-approved medication that may improve this function is modafinil. Studies in animals and healthy adults show that this medication can improve many of these cognitive functions. We plan to study the effects of modafinil on these cognitive processes, by giving various doses of this medication to patients before they perform tasks of these cognitive processes. We predict that when patients receive modafinil, they will perform better on a cognitive test, and that these benefits will depend on the dose given.

Timeline

Start
2008-05
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 100 mg Oral
Subject Modafinil Small molecule 200 mg Oral
Subject Modafinil Small molecule 400 mg Oral

Indications